Table 3.

Adverse events

	n = 16
Adverse event leading to discontinuation	1 (6.3) †
Adverse events leading to dose reduction	3 (18.8) ‡
Grade 3–5 adverse event	0 (0)
Grade 1–2 adverse events
Nausea	8 (50.0)
Dyspepsia	3 (18.8)
Appetite loss	2 (12.5)
Constipation	2 (12.5)
Colonic hemorrhage	1 (6.3)
Dizziness	2 (12.5)
Urinary tract infection	1 (6.3)

Data are presented as numbers (percentages).

^† One patient of temporary discontinuation due to urinary tract infection following a bladder biopsy. Oral semaglutide treatment was temporarily discontinued for 28 days due to urinary tract infection following bladder biopsy, but resumed after recovery.

^‡ All adverse events leading to dose reduction were nausea.